Tags

Type your tag names separated by a space and hit enter

[Treatment of malignancy associated hypercalcemia].
Clin Calcium. 2014 Aug; 24(8):1223-8.CC

Abstract

Malignancy associated hypercalcemia (MAH) is a paraneoplastic syndrome that impairs the quality of life and that can be a direct cause of death. MAH is classified into two major categories : humoral hypercalcemia of malignancy (HHM) and local osteolytic hypercalcemia (LOH) . Bisphosphonates are the gold standard of treatment for MAH, because enhanced resorption causing a massive calcium mobilization from bone plays a central role in the pathogenesis of MAH. Calcitonin can be used initially as an adjunctive therapy, because it takes a few days for bisphosphonates to be effective. Saline infusion is also necessary to improve dehydration and renal insufficiency inevitably accompanying MAH.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Tai N
Third Department of Medicine, Teikyo University Chiba Medical Center, Japan.
Inoue D
No affiliation info available

MeSH

Bone ResorptionCalcitoninDiphosphonatesHumansHypercalcemiaNeoplasmsParaneoplastic SyndromesParathyroid Hormone-Related Protein

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

25065875

Citation

Tai, Nobuyuki, and Daisuke Inoue. "[Treatment of Malignancy Associated Hypercalcemia]." Clinical Calcium, vol. 24, no. 8, 2014, pp. 1223-8.
Tai N, Inoue D. [Treatment of malignancy associated hypercalcemia]. Clin Calcium. 2014;24(8):1223-8.
Tai, N., & Inoue, D. (2014). [Treatment of malignancy associated hypercalcemia]. Clinical Calcium, 24(8), 1223-8. https://doi.org/CliCa140812231228
Tai N, Inoue D. [Treatment of Malignancy Associated Hypercalcemia]. Clin Calcium. 2014;24(8):1223-8. PubMed PMID: 25065875.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Treatment of malignancy associated hypercalcemia]. AU - Tai,Nobuyuki, AU - Inoue,Daisuke, PY - 2014/7/29/entrez PY - 2014/7/30/pubmed PY - 2014/10/18/medline SP - 1223 EP - 8 JF - Clinical calcium JO - Clin Calcium VL - 24 IS - 8 N2 - Malignancy associated hypercalcemia (MAH) is a paraneoplastic syndrome that impairs the quality of life and that can be a direct cause of death. MAH is classified into two major categories : humoral hypercalcemia of malignancy (HHM) and local osteolytic hypercalcemia (LOH) . Bisphosphonates are the gold standard of treatment for MAH, because enhanced resorption causing a massive calcium mobilization from bone plays a central role in the pathogenesis of MAH. Calcitonin can be used initially as an adjunctive therapy, because it takes a few days for bisphosphonates to be effective. Saline infusion is also necessary to improve dehydration and renal insufficiency inevitably accompanying MAH. SN - 0917-5857 UR - https://www.unboundmedicine.com/medline/citation/25065875/[Treatment_of_malignancy_associated_hypercalcemia]_ DB - PRIME DP - Unbound Medicine ER -